Cusack Protocol

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search

The Cusack Protocol is a protocol of various nutritional supplements that can proportedly improve connective tissue integrity and some digestive symptoms in people with Ehlers-Danlos Syndrome.[1] It was created Deborah Cusack, a patient with EDS.[1]

Components[edit | edit source]

Theory[edit | edit source]

The Cusack Protocol aims to regenerate connective tissue and resolve mast cell disease symptoms. It is a treatment strategy that is expected to be continued in the long term, possibly indefinitely, rather than a cure for Ehlers-Danlos syndrome.[2][3]

Evidence[edit | edit source]

Despite anecdotal reports of improvement, neither the protocol nor its components have ever been studied in EDS.[1]

Risks, safety, and side effects[edit | edit source]

Risks are largely unknown due to lack of clinical trials and an absence of medical practitioners reporting on the effects of patients using the Cusack protocol.[1] The Cusack protocol includes eight supplements, so side effects may result from any of these or from combinations of them.

Deborah Cusack has stated that some side effects will be experienced initially, and may last between one day and several weeks in EDS patients, which she refers to as the "healing curve" or a "healing crisis". Cusack states this includes stiff joints]], aching muscles, and that fatigue, mild fever, nausea and headache may also occur.[3]

A mast cell disease flare may also occur in patients with mast cell disease, according to Cusack. There is lack of information about the impact of the protocol on people with other illnesses in addition to EDS, or effects on people without EDS.[3]

These is a lack of information about the safety and risks of taking these supplements with existing medications or other supplements.[3]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. 1.01.11.21.3 The Ehlers Danlos Society (Sep 8, 2017). "HYPERMOBILITY PLENARY SESSSION and Q&A (Transcript)" (PDF). ehlers-danlos.com. Retrieved Oct 4, 2020. 
  2. 2.02.1 Cusack, Deborah. "What Works?". EDS & Polysaccharides. Retrieved Oct 4, 2020. 
  3. 3.03.13.23.33.4 Ehlers-Danlos Support Wilmington (Mar 10, 2016). "Cusack Protocol (slides)". facebook.com. Retrieved Oct 4, 2020. 

adverse reaction - Any unintended or unwanted response to the treatment under investigation in a clinical trial.

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.